AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10449846 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic cholecystectomy
Number of subjects: 36
Study 10449846 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure laparoscopic cholecystectomy
Number of subjects: 36
Study 7843751 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg losartan
Number of subjects: 51
Study 7843751 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enalapril
Number of subjects: 51
Study 7843751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7843751 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg losartan and 20 mg enalapril
Number of subjects: 51
Study 2508149 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study 2508149 — intervention group
Group type: EXPERIMENTAL
Intervention: secobarbital
Number of subjects: 0
Study 2508149 — intervention group
Group type: EXPERIMENTAL
Intervention: marijuana
Number of subjects: 0
Study 2508149 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 29968290 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month recall period
Number of subjects: 5000
Study 29968290 — intervention group
Group type: COMPARATOR
Intervention: 2-week recall period
Number of subjects: 5000
Study 29968290 — intervention group
Group type: COMPARATOR
Intervention: 3-month recall period
Number of subjects: 5000
Study 28639937 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone plus 2 g/kg of IVIG in divided doses within 5 days of the first commencement of steroid therapy
Number of subjects: 170
Study 28639937 — intervention group
Group type: COMPARATOR
Intervention: IV methylprednisolone only
Number of subjects: 170
Study 26315981 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release guanfacine (N=30)
Number of subjects: 62
Study 26315981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=32)
Number of subjects: 62
Study 23146820 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg synthetic oral THC
Number of subjects: 14
Study 23146820 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg synthetic oral THC
Number of subjects: 14
Study 23146820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Sativex (5.4 mg THC, 5.0 mg CBD)
Number of subjects: 14
Study 23146820 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Sativex (16.2 mg THC, 15.0 mg CBD)
Number of subjects: 14
Study 23146820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 23146820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex
Number of subjects: 14
Study 23146820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC
Number of subjects: 14
Study 22027622 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (500 IU/kg) and iron sucrose (200 mg)
Number of subjects: 74
Study 22027622 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 74
Study 19429471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg oral dose)
Number of subjects: 72
Study 17021430 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ SPECT
Number of subjects: 7
Study 17021430 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ SPECT, IMP SPECT, FDG PET
Number of subjects: 7
Study 15158344 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard IFN/ribavirin
Number of subjects: 169
Study 15158344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-IFN/ribavirin
Number of subjects: 169
Study 15158344 — intervention group
Group type: COMPARATOR
Intervention: Serum ferritin
Number of subjects: 169
Study 15158344 — intervention group
Group type: COMPARATOR
Intervention: Hepatic iron concentration (HIC)
Number of subjects: 169
Study 15158344 — intervention group
Group type: COMPARATOR
Intervention: Transferrin saturation levels
Number of subjects: 169
Study 15158344 — intervention group
Group type: COMPARATOR
Intervention: HFE-mutation status
Number of subjects: 169
Study 15158344 — intervention group
Group type: COMPARATOR
Intervention: DiBisceglie score
Number of subjects: 169
Study 15158344 — intervention group
Group type: COMPARATOR
Intervention: Iron grading
Number of subjects: 169
Study 11099284 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 464
Study 11099284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy
Number of subjects: 464
Study 11099284 — intervention group
Group type: COMPARATOR
Intervention: Usual general practitioner care
Number of subjects: 464
Study 9278211 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg daily for 21 days) + Warfarin (25 mg single dose)
Number of subjects: 12
Study 9278211 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (25 mg single dose)
Number of subjects: 12
Study 8338265 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% dextrose in lactated Ringer's solution (RLG1)
Number of subjects: 41
Study 8338265 — intervention group
Group type: COMPARATOR
Intervention: 0.9% dextrose in lactated Ringer's solution (B66)
Number of subjects: 41
Study 8338265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RLG1 and B66)
Number of subjects: 41
Study 3495027 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP‐SMZ (50 mg/kg daily)
Number of subjects: 100
Study 3495027 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 100
Study 3495027 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP‐SMZ (normal G‐6‐PD)
Number of subjects: 100
Study 3495027 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (normal G‐6‐PD)
Number of subjects: 100
Study 29052439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual peroxisome proliferator-activated receptor agonist aleglitazar
Number of subjects: 7226
Study 29052439 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal proB-type natriuretic peptide
Number of subjects: 7226
Study 29052439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of coronary revascularization
Number of subjects: 7226
Study 29052439 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 7226
Study 29052439 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 7226
Study 29052439 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin
Number of subjects: 7226
Study 29052439 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin
Number of subjects: 7226
Study 29052439 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior coronary artery bypass
Number of subjects: 7226
Study 29052439 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior myocardial infarction
Number of subjects: 7226
Study 27160738 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment (motor learning-based treatment)
Number of subjects: 28
Study 27160738 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment if needed after the study)
Number of subjects: 28
Study 23928955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined general with spinal anesthesia
Number of subjects: 38
Study 23928955 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 38
Study 22951500 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (200 IU/d)
Number of subjects: 222
Study 22951500 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg/d orally for 14 days quarterly)
Number of subjects: 222
Study 22951500 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d)
Number of subjects: 222
Study 22951500 — intervention group
Group type: COMPARATOR
Intervention: Calcium plus Vitamin D3 (1000 mg/d calcium plus 800 IU/d vitamin D3)
Number of subjects: 222
Study 20102746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Mycophenolate Mofetil (MMF)
Number of subjects: 89
Study 20102746 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus + Methotrexate (MTX)
Number of subjects: 89
Study 18202889 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary duct closure
Number of subjects: 80
Study 18202889 — intervention group
Group type: COMPARATOR
Intervention: T‐tube drainage
Number of subjects: 80
Study 16537378 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral N-acetylcysteine (0.6 to 1.0 g three times daily, for 4 weeks)
Number of subjects: 18
Study 16537378 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral N-acetylcysteine
Number of subjects: 18
Study 12773587 — intervention group
Group type: EXPERIMENTAL
Intervention: Pallidotomy surgery
Number of subjects: 0
Study 12773587 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 0
Study 12773587 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease (before surgery)
Number of subjects: 0
Study 12773587 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease (after surgery)
Number of subjects: 0
Study 11130773 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day for 8 days)
Number of subjects: 11
Study 11130773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9058689 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled heparin (15,000 units USP/ml, 4 ml)
Number of subjects: 17
Study 9058689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8104097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous benztropine (2 mg)
Number of subjects: 6
Study 8104097 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg)
Number of subjects: 6
Study 8104097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 6
Study 3732769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodiol (chenodeoxycholate), 750 mg/day
Number of subjects: 81
Study 3732769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodiol (chenodeoxycholate), 375 mg/day
Number of subjects: 81
Study 3732769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodiol (chenodeoxycholate)
Number of subjects: 81
Study 3732769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 31876024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Number of subjects: 47
Study 31876024 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 29779170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks)
Number of subjects: 14
Study 29779170 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 14
Study 28556188 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 13
Study 28556188 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study 25805405 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive imagery cognitive bias modification (CBM)
Number of subjects: 75
Study 25805405 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 75
Study 25805405 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CBM and control)
Number of subjects: 75
Study 23258641 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal electromotive administration of verapamil (10 mg) and dexamethasone (4 mg)
Number of subjects: 60
Study 23258641 — intervention group
Group type: COMPARATOR
Intervention: Intra-lesional injection of verapamil (10 mg) and dexamethasone (4 mg)
Number of subjects: 60
Study 23258641 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal electromotive administration of verapamil and dexamethasone
Number of subjects: 60
Study 21291509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teams that exhibited stated recognition of the emergency (eclampsia) earlier.
Number of subjects: 114
Study 21291509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teams that managed the critical task using closed‐loop communication.
Number of subjects: 114
Study 21291509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teams that administered magnesium sulfate within the allocated time (10 minutes).
Number of subjects: 114
Study 20081574 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance exercise programme using heel raises in addition to compression
Number of subjects: 40
Study 20081574 — intervention group
Group type: COMPARATOR
Intervention: Usual care in addition to compression
Number of subjects: 40
Study 16622171 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support system (CDSS) added to computerized physician order entry (CPOE) system
Number of subjects: 445
Study 16622171 — intervention group
Group type: COMPARATOR
Intervention: Control units without alerts
Number of subjects: 445
Study 15050862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg and 2 mg on 2 successive days)
Number of subjects: 52
Study 15050862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 11777667 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare program (n = 62)
Number of subjects: 145
Study 11777667 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 51)
Number of subjects: 145
Study 9489052 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 111
Study 9489052 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone doses
Number of subjects: 111
Study 9489052 — intervention group
Group type: EXPERIMENTAL
Intervention: Year of enrollment
Number of subjects: 111
Study 9489052 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable income
Number of subjects: 111
Study 9489052 — intervention group
Group type: EXPERIMENTAL
Intervention: History of opioid use
Number of subjects: 111
Study 7957160 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diet
Number of subjects: 90
Study 7957160 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical training
Number of subjects: 90
Study 7957160 — intervention group
Group type: COMPARATOR
Intervention: Unlimited exercise
Number of subjects: 90
Study 7957160 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum diet
Number of subjects: 90
Study 7957160 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 90
Study 3612036 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive instrument for acute ischemic heart disease
Number of subjects: 0
Study 29493105 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3®
Number of subjects: 19
Study 29493105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 27071477 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Four weeks of APA-focused training involving catching a medicine ball while standing
Number of subjects: 6
Study 27071477 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No training
Number of subjects: 6
Study 24694794 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (2 g 3 times daily for 8 weeks)
Number of subjects: 249
Study 24694794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 24694794 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120
Number of subjects: 249
Study 24694794 — intervention group
Group type: COMPARATOR
Intervention: AST-120 and Placebo
Number of subjects: 249
Study 22348845 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml 0.75% ropivacaine to the tonsil lodge
Number of subjects: 90
Study 22348845 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg i.v. tramadol
Number of subjects: 90
Study 22348845 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (placebo group)
Number of subjects: 90
Study 21054850 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective V(2)R-antagonist (1 μg/kg per hour)
Number of subjects: 21
Study 21054850 — intervention group
Group type: COMPARATOR
Intervention: AVP (0.05 μg/kg per hour)
Number of subjects: 21
Study 21054850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 21
Study 18320520 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg intravitreal bevacizumab
Number of subjects: 40
Study 18320520 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 40
Study 18320520 — intervention group
Group type: EXPERIMENTAL
Intervention: Avastin-treated eyes
Number of subjects: 40
Study 15947724 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-ended STAR questionnaire
Number of subjects: 104
Study 15947724 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-ended STAR questionnaire
Number of subjects: 104
Study 15947724 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report instruments
Number of subjects: 104
Study 12356631 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-hexanoyltaxol-eluting stents (qDES)
Number of subjects: 122
Study 12356631 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 122
Study 10686834 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 117
Study 10686834 — intervention group
Group type: COMPARATOR
Intervention: Wire fixation
Number of subjects: 117
Study 10686834 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical oral health (OHSQ)
Number of subjects: 117
Study 10686834 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Severity Index (GSI) score from SCL-90-R
Number of subjects: 117
Study 10686834 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial scale score from SIP
Number of subjects: 117
Study 10686834 — intervention group
Group type: EXPERIMENTAL
Intervention: GSI, SIP, and OHSQ
Number of subjects: 117
Study 8850174 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum cTnT
Number of subjects: 79
Study 8850174 — intervention group
Group type: COMPARATOR
Intervention: Increased serum CK‐MB
Number of subjects: 79
Study 8850174 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative serum cTnT
Number of subjects: 79
Study 8850174 — intervention group
Group type: COMPARATOR
Intervention: Negative serum CK‐MB
Number of subjects: 79
Study 8850174 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexplained cTnT elevations
Number of subjects: 79
Study 1928808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 49
Study 1928808 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 49
Study 6285280 — intervention group
Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 50
Study 6285280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31191268 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement
Number of subjects: 60
Study 31191268 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Number of subjects: 60
Study 31191268 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (control)
Number of subjects: 60
Study 29063307 — intervention group
Group type: EXPERIMENTAL
Intervention: P4HB mesh
Number of subjects: 121
Study 29786356 — intervention group
Group type: EXPERIMENTAL
Intervention: ACNB+COX‐2 (group A)
Number of subjects: 90
Study 29786356 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 (group B)
Number of subjects: 90
Study 29786356 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90
Study 25091284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GR liquid meal replacement (Glucerna SR)
Number of subjects: 20
Study 25091284 — intervention group
Group type: COMPARATOR
Intervention: Free-choice breakfast
Number of subjects: 20
Study 25091284 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic control breakfast
Number of subjects: 20
Study 21992533 — intervention group
Group type: EXPERIMENTAL
Intervention: More Intensive (MI) regimen of belatacept
Number of subjects: 666
Study 21992533 — intervention group
Group type: EXPERIMENTAL
Intervention: Less Intensive (LI) regimen of belatacept
Number of subjects: 666
Study 21992533 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 666
Study 21265120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasonat
Number of subjects: 0
Study 17671059 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer kiosk intervention (Safety in Seconds program)
Number of subjects: 759
Study 17671059 — intervention group
Group type: COMPARATOR
Intervention: Control group (report on other child health topics)
Number of subjects: 759
Study 15691303 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 200
Study 15691303 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily
Number of subjects: 200
Study 12609711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro12Ala polymorphism in PPAR-gamma gene
Number of subjects: 381
Study 10709535 — intervention group
Group type: EXPERIMENTAL
Intervention: Active distraction technique (repeated deep breathing and blowing out air)
Number of subjects: 50
Study 10709535 — intervention group
Group type: COMPARATOR
Intervention: Control group (injection given in a slow manner without the distraction technique)
Number of subjects: 50
Study 7778005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar body support (LBS)
Number of subjects: 10
Study 7778005 — intervention group
Group type: COMPARATOR
Intervention: Flat conventional mattress
Number of subjects: 10
Study 1683217 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day oral celiprolol
Number of subjects: 17
Study 1683217 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/day oral nicardipine
Number of subjects: 17
Study 7299629 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in 12 pleasurable activities
Number of subjects: 0
Study 7299629 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in 2 pleasurable activities
Number of subjects: 0
Study 7299629 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activities, retesting after 1 month)
Number of subjects: 0
Study 31198048 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity coaching program (18 months, monthly follow-up by physiotherapist)
Number of subjects: 380
Study 31198048 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 380
Study 31198048 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity coaching program
Number of subjects: 380